CRNX Crinetics Pharmaceuticals, Inc.
CRNX Crinetics Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-08-17 1 bull converging
POC $83.57 · VWAP $57.82 · +46.6% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
CRNX Price Structure
Loading timeframes…
Peers
Every watchlist CRNX belongs to, members best 30-day change first — CRNX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported EPS $-1.14 versus analyst consensus of $-1.18 (+3.7%).
full note →Against street estimates
How CRNX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about CRNX from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 18 days ago · Jul 31
- Crinetics downgraded to Neutral from Buy at UBS
- Crinetics Pharmaceuticals (CRNX) to be Acquired by Vertex Pharmaceuticals for $10 Billion
- Crinetics to be acquired by Vertex for $85 per share
- Crinetics stocks surge after Vertex agrees to $10B cash buyout
- Vertex Pharmaceuticals to Acquire Crinetics for $10B
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
CRNX research tape
22 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.